James Dahlvang
he/him/his
About
Research
Publications
2023
Ablation of SYK kinase from expanded primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production
Dahlvang J, Dick J, Sangala J, Kennedy P, Pomeroy E, Snyder K, Moushon J, Thefaine C, Wu J, Hamilton S, Felices M, Miller J, Walcheck B, Webber B, Moriarity B, Hart G. Ablation of SYK kinase from expanded primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production. The Journal Of Immunology 2023, 210: 1108-1122. PMID: 36881874, PMCID: PMC10073313, DOI: 10.4049/jimmunol.2200488.Peer-Reviewed Original Research
2021
Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth
Hintz H, Snyder K, Wu J, Hullsiek R, Dahlvang J, Hart G, Walcheck B, LeBeau A. Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth. Cancer Immunology Research 2021, 9: 1270-1282. PMID: 34452926, PMCID: PMC9119026, DOI: 10.1158/2326-6066.cir-21-0178.Peer-Reviewed Original Research